Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Several projects are on-going investigating efficacy, safety, and potential drug-drug interactions of antimalarial drugs when used in novel combination treatments. Particular focus will be on triple combination therapy with or without other transmission and/or vector control agents such as primaquine and/or ivermectin. Pharmacokinetic and pharmacodynamic modelling of these combinations aims to inform treatment policy of multi-drug resistant malaria and provide treatment options in malarial elimination campaigns.